Millions of patients could benefit if only there were viable production methods for the most complex biotherapeutics in clinical pipelines.

For most complex next-generation biopharmaceuticals, production costs to date make these lifesavers prohibitively expensive, with a single therapeutic dose sometimes costing more than one million US dollars. With our optogenetic approach, we will help make production substantially more cost-effective.

As an enabling technology, Ningaloo´s proprietary bio-digital platform will pave the way for advanced curing options in areas as diverse as cancer, immunology, gene therapy or neurodegenerative disease therapies.

Advances in optogenetics and synthetic biology will make it possible to boost both bioproduction quality and yield in making the most promising upcoming drugs: next gen biopharmaceuticals.

Photoswitches inside living cells can be used to optically control processes as diverse as membrane potentials, cellular signal transduction, protein translocation or gene expression. We will use this wealth of new possibilities to control bioproduction processes at different levels.

One of the biggest challenges in biopharma is scaling up from microliter scale to hundreds of liters when moving from R&D to process development and finally to commercial production of a biopharmaceutical drug. With our opto-bioproduction systems, we aim to provide dynamic and precise real-time process control across the different culture formats, while ensuring improved scalability.